Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?
Daniel J Scherer,1 Stephen J Nicholls2 1Cardiovascular Investigation Unit, Royal Adelaide Hospital, 2South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, SA, Australia Abstract: Despite the clinical benefits of lowering levels of low-density lipoprotein cholest...
Main Authors: | Scherer DJ, Nicholls SJ |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-03-01
|
Series: | Vascular Health and Risk Management |
Online Access: | http://www.dovepress.com/lowering-triglycerides-to-modify-cardiovascular-risk-will-icosapent-de-peer-reviewed-article-VHRM |
Similar Items
-
Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides
by: Bhatt, D.L, et al.
Published: (2022) -
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia
by: M Aseem Basha
Published: (2019-01-01) -
The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk
by: Muhammad Shoaib Khan, et al.
Published: (2021-01-01) -
Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
by: Jia X, et al.
Published: (2020-01-01) -
Icosapent ethyl: scientific and legal controversies
by: Gregory Curfman, et al.
Published: (2021-06-01)